论文部分内容阅读
培氟沙星治疗１０９３例细菌感染，包括男性６４９例，女性４４４例，平均年龄４３．４岁。病种包括呼吸系统感染、泌尿系统感染、肠道感染、皮肤软组织感染、外科及其它部位感染。服药剂量为０．４～１．２ｇ／ｄ，其中０．４ｇ／ｄ４９８例，０．６ｇ／ｄ９８例，０．８ｇ／ｄ４６８例，平均疗程８ｄ。痊愈率为６５．３％，有效率为９０．８％，细菌清除率为７６．９％。不良反应发生率为９．５％（１０４／１０９３），其中消化系统６２例，神经系统２４例，皮疹、搔痒共１０例，早搏１例，ＡＬＴ升高７例。本试验中６５岁以上患者１５１例，其临床疗效与不良反应发生率与总体相似。培氟沙星不同剂量有效性与安全性分析结果显示，随药物剂量增加，临床疗效和不良反应发生率均增高，统计学分析无明显性差异（Ｐ＞０．０５）。
Pefloxacin treatment of 1093 cases of bacterial infections, including 649 males and 444 females, with an average age of 43.4 years. Diseases include respiratory infections, urinary tract infections, intestinal infections, skin and soft tissue infections, surgical and other infections. The dosage was 0.4 ~ 1.2g / d, of which 0.4g / d 498 cases, 0.6g / d 98 cases, 0.8g / d 468 cases, the average course of treatment 8d. The cure rate was 65.3%, the effective rate was 90.8% and the bacterial clearance rate was 76.9%. The incidence of adverse reactions was 9.5% (104/1093), including 62 cases of digestive system, 24 cases of nervous system, 10 cases of rash and itch, 1 case of premature beat and 7 cases of ALT. 151 cases of patients over the age of 65 in this trial, its clinical efficacy and adverse reactions and the overall incidence of similar. Pefloxacin efficacy and safety analysis of different doses showed that with the drug dose increases, the clinical efficacy and adverse reactions were increased, no significant statistical difference (P> 0.05).